Gemfibrozil modifies acyl composition of liver microsomal phospholipids from guinea-pigs without promoting peroxisomal proliferation.
Treatment with gemfibrozil modifies acyl composition of hepatic microsomal phosphatidylcholine and phosphatidylethanolamine in guinea-pigs. Palmitic (16:0) and palmitoleic (16:1) fatty acids are increased, and stearic (18:0) and oleic (18:1) are decreased; further, while linoleic acid [18:2 (n-6)] is increased by gemfibrozil treatment, the other constituents of the n-6 fatty acids family, including arachidonic acid [20:4 (n-6)], are decreased. As gemfibrozil is a potent inhibitor of fatty acid elongation in vitro (Sánchez et al., FEBS Lett 300: 89-92, 1992), the inhibition of this enzyme system by gemfibrozil treatment could be responsible for the observed results in vivo. These changes in fatty acid composition are accompanied by a decrease in serum lipids and, more important, are independent of peroxisomal proliferation.
Vázquez
M
M
Unidad de Farmacología y Farmacognosia, Facultad de Farmacia, Universidad de Barcelona, Spain.
Alegret
M
M
Adzet
T
T
Merlos
M
M
Laguna
J C
JC
D000818:Animals; D001835:Body Weight / Q000187:drug effects; D005227:Fatty Acids / Q000032:analysis; D015248:Gemfibrozil / Q000494:pharmacology*; D006168:Guinea Pigs; D008830:Microbodies / Q000187:drug effects; D008862:Microsomes, Liver / Q000187:drug effects*; D009929:Organ Size / Q000187:drug effects; D010084:Oxidation-Reduction; D010713:Phosphatidylcholines / Q000737:chemistry / Q000378:metabolism; D010714:Phosphatidylethanolamines / Q000737:chemistry / Q000378:metabolism; D010743:Phospholipids / Q000378:metabolism*
D005227:Fatty Acids; D010713:Phosphatidylcholines; D010714:Phosphatidylethanolamines; D010743:Phospholipids; D015248:Gemfibrozil